Karyopharm Therapeutics (KPTI) Announces Top-Line Selinexor Phase 2b Data in Multiple Myeloma

Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM Results

Baird analyst Michael Ulz reiterated an Outperform rating and $16 price target on Karyopharm Therapeutics (NASDAQ: KPTI) following Phase 2b STORM data, which was positive as expected.

Ulz commented, "Selinexor achieved an overall response rate (ORR) of 20% in penta-refractory multiple myeloma... More